These FTSE shares don’t have the highest yields. But Edward Sheldon believes they could deliver attractive returns in the ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

The UK based drug firm GSK has agreed to pay up to $2.2bn (£1.7bn; €2bn) to settle claims that the heartburn drug ranitidine (previously marketed in the US as Zantac) caused cancer. The deal, ...

John Maraganore, the former CEO of Alnylam Pharmaceuticals, launched City Therapeutics, a new startup with $135 million from ...

British pharmaceutical company GSK has agreed to pay $2.3 billion to settle lawsuits alleging that its heart burn medication Zantac caused cancer. GSK has settled 80,000 Zantac lawsuit. Watch to know ...

Zantac was pulled from shelves in 2019 amid panic that a key ingredient - ranitidine - could cause cancer, plunging GSK and ...

GSK to resolve 93% of US state court Zantac product liability cases for up to $2.2 billion: London, UK Friday, October 11, 2024, 14:00 Hrs [IST] GSK plc announced that it has reac ...

EUROPEAN shares closed lower on Thursday (Oct 10), with defence and industrial stocks leading losses, after data showed US inflation ticked higher, while investors waited for France to unveil its 2025 ...

GSK shares jumped on Thursday after the UK drugmaker reached a settlement of up to $2.2bn to resolve the vast majority of cases linked to its heartburn medicine Zantac.

Shares slipped in New York and Europe Thursday as the latest US inflation report strengthened the case for a slower pace of ...

Lawyers representing 10 groups of plaintiffs, or 80,000 liability cases across the US, have backed the payout. There remain another few thousand cases not covered by the payout. GSK will also pay a ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...